Clinical trial NCT01017185: Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Official title: Phase I Trial of Intratumoral Administration of HF10, A Replication Competent Herpes Simplex Virus Type 1, in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Refractory Head and Neck Cancer
Squamous Cell Carcinoma, Skin
Carcinoma of the Breast
Malignant Melanoma
Lead sponsor: Takara Bio Inc.
Sponsor class: INDUSTRY
First posted: 2009-11-20
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.

Detailed description: This is an open label, non-randomized, multicenter, two-stage, dose escalation Phase I study evaluating single and repeated intratumoral injections of the oncolytic virus, HF10, in patients with refractory head and neck cancer, or solid tumors with cutaneous and/or superficial lesions (e.g., squamous cell carcinoma of the skin, carcinoma of the breast, and malignant melanoma).

Stage 1: Stage 1 of the study will investigate dose escalation of a single intratumoral injection over the following dose levels: 1 x 10\^5 TCID50, 3 x 10\^5 TCID50, 1 x 10\^6 TCID50, and 1 x 10\^7 TCID50. In Stage 1, it is planned that 3 patients will be enrolled per single dose cohort. Within each single dose cohort, accrual will temporarily be suspended after the first patient is entered and the patient will be followed for safety and for viral distribution and elimination. The patients in Stage 1 must be seropositive for HSV-1.

Stage 2: Stage 2 will evaluate repeated intratumoral injections of HF10 at dose levels of 1 x 10\^6 TCID50/dose and 1 x 10\^7 TCID50/dose. Three patients will be enrolled in each of the repeated dose cohorts. In Stage 2, the first patient treated in each repeated dose cohort must be seropositive for HSV-1. Patients in the repeated dose cohort will receive a total of four intratumoral injections in the same lesion.

Following completion of dosing in the repeated dose cohorts, an expansion cohort of three additional patients will be treated at the highest tolerated dose level.

Eligibility criteria: Inclusion Criteria

* Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy, or endocrine therapy) and for which no curative options exist, including, but not limited to:

  * Squamous cell carcinoma of the head and neck
  * Squamous cell carcinoma of the skin
  * Carcinoma of the breast
  * Malignant melanoma
* Patients may have had any kind and number of prior cancer therapies.
* Patients must have measurable non-visceral lesions that are evaluable by the RECIST method
* The tumor mass to be treated must be non-visceral and adequate for injection (i.e., more than 2 cm away from major vascular structures) and measurement by RECIST.
* Patients in Stage 1 must be seropositive for HSV-1.
* The first patient enrolled into each cohort in Stage 2 must be seropositive for HSV-1.
* Patients must be ≥ 18 years of age.
* Patients must have a life expectancy ≥ 12 weeks
* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
* Patients must have adequate hepatic function, as defined as

  * Total bilirubin levels ≤ 1.5 x upper limit of normal (ULN)
  * AST/ALT levels ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
* Patients must have adequate renal function as defined as serum creatinine ≤ 1.5 x ULN or creatinine clearance (calculated) ≥ 60 mL/min/1.73 m2 for patients with creatinine \> 1.5 x ULN
* Patients must have adequate bone marrow function, as defined as

  * Absolute neutrophil count ≥ 1,500/μL and
  * Platelet count ≥ 100,000/μL
* Patients must have no known bleeding diathesis or coagulopathy that would make intratumoral injection or biopsy unsafe.
* Men and women of childbearing potential must agree to use adequate contraception prior to study entry and for up to six months.
* Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
* Patients must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria

* Patients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or adverse events \> Grade 1, except alopecia, resulting from agents administered more than 4 weeks prior to HF10 injection.
* Patients with a history of significant tumor bleeding, or coagulation or bleeding disorders.
* Patients with nasopharyngeal tumors.
* Patients with deep (below the platysma muscle layer) ulcerative tumors.
* Patients with target tumors that could potentially invade a major vascular structure(s) (e.g., innominate artery, carotid artery), based on unequivocal imaging findings, as determined by a radiologist.
* Patients with Grade ≥ 1 pre-existing neurologic abnormalities (CTCAE version 3.0).
* Patients who have been hospitalized for emergent conditions requiring inpatient evaluation, treatment or procedure during the 30 days prior to entry on study. In addition, emergent conditions requiring inpatient evaluation, treatment or procedure must have resolved or be medically stable and not severe for 30 days prior to entry on study.
* Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection. Patients will be tested for HIV during pre-treatment screening.
* Patients receiving steroids or immunosuppressive agents, e.g., for rheumatoid arthritis
* Concurrent use of any other investigational agents.
* Presence or history of central nervous system metastasis.
* Pregnant or breastfeeding women;women desiring to become pregnant within the timeframe of the study are also excluded.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Primary outcomes:
measure: Assessment of the local tumor response of the HF10-injected tumor by a modified target Response Evaluation Criteria In Solid Tumors (RECIST) method
timeFrame: one year
Secondary outcomes:
measure: Adverse events, vital signs, electrocardiogram(ECG), clinical laboratory tests, and physical exercise
timeFrame: one year
measure: Histological tumor response by biopsy
timeFrame: one year
measure: Overall tumor response of the HF10-injected tumor plus additional non-injected target tumors.
timeFrame: one year
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: Portland
country: United States
facility: Oregon Health and Science University
state: Oregon
city: Pittsburgh
country: United States
facility: University of Pittsburgh
state: Pennsylvania
city: Dallas
country: United States
facility: Mary Crowley Cancer Research Center
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
Study officials:
affiliation: Division of Head and Neck Cancer Surgery, University of Pittsburgh Cancer Institute
name: Robert L Ferris, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: